EUVIMEDEUVIMED entdecken
Multizentrische Studie

Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer

Cheng-Yu Tang, Shih-Hung Yang, Chung-Pin Li, Yung-Yeh Su, Sz-Chi Chiu, Li-Yuan Bai, Yan-Shen Shan, Li-Tzong Chen, Shih-Chang Chuang, De-Chuan Chan, Chia-Jui Yen, Cheng-Ming Peng und 5 weitere

Pancreatology · 2024

DOI: 10.1016/j.pan.2024.03.014 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pancreatology, 2024. Verfasst von Cheng-Yu Tang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, College of Medicine, National Yang Ming Chiao Tung Univ…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Leucovorin, Fluorouracil, Irinotecan. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/OBJECTIVES: Liposomal irinotecan plus 5-fluorouracil and leucovorin (nal-IRI + 5-FU/LV) provides survival benefits for metastatic pancreatic adenocarcinoma (mPDAC) refractory to gemcitabine-based treatment, mainly gemcitabine plus nab-paclitaxel (GA), in current practice. Gemcitabine plus S-1 (GS) is another commonly administered first-line regimen before nab-paclitaxel reimbursement; however, the efficacy and safety of nal-IRI + 5-FU/LV for mPDAC after failed GS treatment has not been reported and was therefore explored in this study. METHODS: In total, 177 patients with mPDAC received first-line GS or GA treatment, followed by second-line nal-IRI + 5-FU/LV treatment (identified from a multicenter retrospective cohort in Taiwan from 2018 to 2020); 85 and 92 patients were allocated to the GS and GA groups, respectively. Overall survival (OS), time-to-treatment failure (TTF), and adverse events were compared between the two groups. RESULTS: The baseline characteristics of the two groups were generally similar; however, a higher median age (67 versus 62 years, p < 0.001) and fewer liver metastases (52% versus 78%, p < 0.001) were observed in the GS versus GA group. The median OS was 15.0 and 15.9 months in the GS and GA groups, respectively (p = 0.58). The TTF (3.1 versus 2.8 months, p = 0.36) and OS (7.6 versus 6.7 months, p = 0.83) after nal-IRI treatment were similar between the two groups. More patients in the GS group developed mucositis during nal-IRI treatment (15% versus 4%, p = 0.02). CONCLUSIONS: The efficacy of second-line nal-IRI +5-FU/LV treatment was unaffected by prior S-1 exposure. GS followed by nal-IRI treatment is an alternative treatment sequence for patients with mPDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsLeucovorinFluorouracilIrinotecanTegafurAntineoplastic Combined Chemotherapy ProtocolsDrug CombinationsOxonic AcidHumansMiddle AgedMaleFemaleAgedRetrospective StudiesLiposomesTreatment OutcomeNeoplasm MetastasisAdultPaclitaxel

Stichwörter der Autor:innen

GemcitabineNab-paclitaxelPancreatic adenocarcinoma

Substanzen

LeucovorinFluorouracilIrinotecanTegafurDrug CombinationsOxonic AcidS 1 (combination)LiposomesPaclitaxel

Autor:innen und Institutionen

  • Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Oncology, National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Division of Clinical Skills Training, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan;…
  • Department of Oncology, National Cheng Kung University Hospital, Taipei, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
  • PharmaEngine, Inc., Taipei, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, China Medical University Hospital and China Medical University, Taichung, Taiwan.

Förderung

  • National Science and Technology Council

Zitieren

APA

Tang, C. Y., Yang, S. H., Li, C. P., Su, Y. Y., Chiu, S. C., Bai, L. Y., Shan, Y. S., Chen, L. T., Chuang, S. C., Chan, D. C., Yen, C. J., Peng, C. M., Chiu, T. J., Chen, Y. Y., Chen, J. S., Chiang, N. J., & Chou, W. C. (2024). Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. Pancreatology. https://doi.org/10.1016/j.pan.2024.03.014

Vancouver

Tang CY, Yang SH, Li CP, Su YY, Chiu SC, Bai LY, et al. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. Pancreatology. 2024. doi:10.1016/j.pan.2024.03.014

BibTeX
@article{Tang2024,
  author = {Tang, Cheng-Yu and Yang, Shih-Hung and Li, Chung-Pin and Su, Yung-Yeh and Chiu, Sz-Chi and Bai, Li-Yuan and Shan, Yan-Shen and Chen, Li-Tzong and Chuang, Shih-Chang and Chan, De-Chuan and Yen, Chia-Jui and Peng, Cheng-Ming and Chiu, Tai-Jan and Chen, Yen-Yang and Chen, Jen-Shi and Chiang, Nai-Jung and Chou, Wen-Chi},
  title = {Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer},
  journal = {Pancreatology},
  year = {2024},
  doi = {10.1016/j.pan.2024.03.014}
}
Kostenlos starten →